United Health Products (UEEC) Q3 2024 earnings summary

Executive summary

• Focused on obtaining FDA Class III PMA for CelluSTAT hemostatic gauze, pausing commercial activities to prioritize regulatory approval.

• No revenue generated in Q3 or the nine months ended September 30, 2024, as resources were allocated to regulatory efforts.

• Net loss for Q3 2024 was $303,662, an improvement from $485,732 in Q3 2023; nine-month net loss was $1,187,621, down from $2,151,349 year-over-year.

• Operating expenses decreased due to lower R&D, legal, and litigation settlement costs.

• Gained $115,085 from settlement of vendor debt, contributing to reduced net loss.

Financial highlights

• Q3 2024 operating expenses: $391,903, down from $450,451 in Q3 2023.

• Nine-month operating expenses: $1,222,174, down from $1,979,882 year-over-year.

• Cash on hand at September 30, 2024: $43,783, down from $95,420 at year-end 2023.

• Net cash used in operations for nine months: $1,013,278; net cash provided by financing: $961,641.

• No revenue recognized in 2024 due to regulatory focus.

Outlook and guidance

• Awaiting FDA response to Class III PMA; additional clinical data requested for surgical applications in organ space.

• Considering commercial partnerships or sale/merger post-approval; no assurance of FDA approval or transaction.

• Ongoing evaluation of financing options to support operations until regulatory and commercial milestones are achieved.